Voranigo vorasidenib Updated Nov 5
Voranigo has no pending binary catalyst. Investors should track Servier's commercial execution and quarterly royalty receipts reported by RPRX. RPRX's next major catalyst is the November 27, 2026 PDUFA for neladalkib (a different drug), which is unrelated to Voranigo. Voranigo's contribution to RPRX's value will unfold gradually through sales growth and market expansion across its approved territories.
- First and only FDA-approved targeted therapy for Grade 2 IDH-mutant glioma, addressing a clear unmet need with no direct competition.
- Phase 3 INDIGO data showed compelling efficacy (median PFS 27.7 months vs. 11.1 months for placebo), and extended follow-up at ASCO 2026 showed median PFS of 44.1 months, reinforcing durable benefit.
- Royalty Pharma projects peak annual sales above $1 billion, which would generate over $150 million in annual royalty revenue for RPRX at the 15% rate.
- Royalty Pharma is not the developer or marketer of Voranigo; it only holds a royalty interest. It has no control over Servier's pricing, commercialization, or manufacturing.
- The addressable patient population is narrow (Grade 2 IDH-mutant glioma), which may limit peak sales potential despite high per-patient pricing.
- NICE draft guidance in the UK (March 2026) recommends Voranigo for NHS use, but reimbursement negotiations and market access in Europe could affect the pace of uptake.